nRichDX Announces Appointment of RNA Liquid Biopsy Leader Daniel Kim, PhD, to Scientific Advisory Board

Internationally recognized scientist brings expertise in liquid biopsy, RNA biomarker discovery, and early cancer detection to help guide the advancement of nRichDX's platform of liquid biopsy sample extraction solutions.

IRVINE, Calif., Nov. 10, 2026 /PRNewswire/ -- nRichDX, an emerging leader in liquid biopsy sample preparation and extraction, announced the appointment of Daniel Kim, PhD, to its Scientific Advisory Board ahead of the company's launch of its fully automated Revolution Pro™ instrument at the Association of Molecular Pathology (AMP) meeting occurring Nov 11-14 in Seattle, WA. Dr. Kim brings extensive expertise in RNA liquid biopsy technology development, RNA profiling, and the discovery of molecular biomarkers for the early detection of cancer and other diseases.

Dr. Kim is an Assistant Professor at the University of California, Santa Cruz, an Associate Member of the Canary Center at Stanford University for Cancer Early Detection, and a Research Scholar of the American Cancer Society. He also serves as Co-Chair of the National Institutes of Health (NIH) Liquid Biopsy Scientific Interest Group and Co-Chair of the International Society for Extracellular Vesicles (ISEV) RNA Task Force.

His appointment strengthens nRichDX's scientific advisory expertise as the company optimizes and advances sample preparation solutions supporting research in cell-free RNA (cfRNA), cell-free DNA (cfDNA), and circulating cell-free total nucleic acids (cfTNA). Dr. Kim's research also encompasses the integration of transcriptomics, extracellular vesicle analysis and AI-driven informatics. He also has a specific interest in utilizing long-read nanopore sequencing to investigate disease biology and therapeutic development.

Dr. Kim has been a featured podium speaker at prestigious conferences such as the American Association for Cancer Research (AACR) Annual Meeting, European Association for Cancer Research (EACR) Annual Congress, the International Society of Liquid Biopsy (ISLB) Annual Congress, Precision Medicine World Conference (PMWC), Liquid Biopsy for Precision Oncology Summit, and the Next Generation Dx Summit held annually in Washington D.C.

"Daniel brings an exceptional understanding of RNA biology and the technologies needed to translate circulating cell-free molecular signals into meaningful scientific insights. His perspective will help guide our efforts to address the sample preparation needs of assay developers advancing non-invasive liquid biopsy solutions, particularly in early cancer detection," said nRichDX CEO William Curtis. "The timing is optimal as the company launches its fully automated Revolution Pro™ device to assist with large scale R&D projects and translation medicine, as potential life-saving new liquid biopsy tests are rapidly moving into the clinic."

RNA-based liquid biopsy approaches offer a way to investigate dynamic molecular changes associated with disease. Preparing samples and extracting target signal for these applications requires careful attention to the recovery of rare analytes and compatibility with downstream analysis. As a Scientific Advisory Board member, Dr. Kim will also provide scientific guidance on emerging RNA research to help optimize requirements associated with downstream next-generation molecular profiling technologies.

"Circulating cell-free RNA offers a rich view into disease biology, with exciting possibilities for early detection in the clinic, as well as biomarker discovery, therapeutic research and translational medicine." said Kim. "Upstream sample preparation and enrichment is a critical part of ensuring a high yield of target signal is available for optimal, consistent diagnostic test results. I look forward to working with nRichDX at an exciting time in the company's lifecycle to help advance solutions that support the evolving needs of the broader liquid biopsy community."

For more information, visit www.nrichdx.com and follow on LinkedIn

ABOUT nRichDX

nRichDX provides an innovative liquid biopsy sample preparation platform focused on analyte extraction and is designed to support and optimize assay development and clinical laboratory workflows. Its Revolution platform enables efficient recovery of cfDNA, cfRNA, and cfTNA from flexible sample volumes, with scalable automation options including the fully automated Revolution Pro. By optimizing molecular recovery, nRichDX helps advance assay sensitivity and early cancer detection.

MEDIA CONTACT
Angela Shelley
[email protected] 
949.698.0493

SOURCE nRichDX